WO2021090214A3 - Berbérine bertrypanosomial®, ses compositions et leur utilisation - Google Patents

Berbérine bertrypanosomial®, ses compositions et leur utilisation Download PDF

Info

Publication number
WO2021090214A3
WO2021090214A3 PCT/IB2020/060383 IB2020060383W WO2021090214A3 WO 2021090214 A3 WO2021090214 A3 WO 2021090214A3 IB 2020060383 W IB2020060383 W IB 2020060383W WO 2021090214 A3 WO2021090214 A3 WO 2021090214A3
Authority
WO
WIPO (PCT)
Prior art keywords
berberine
sucrosomial
sucrester
impairment
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/060383
Other languages
English (en)
Other versions
WO2021090214A2 (fr
Inventor
Andrea Lacorte
Elisa BRILLI
Germano Tarantino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alesco SRL
Original Assignee
Alesco SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102019000020316A external-priority patent/IT201900020316A1/it
Priority claimed from IT102019000020290A external-priority patent/IT201900020290A1/it
Priority claimed from IT102019000020300A external-priority patent/IT201900020300A1/it
Application filed by Alesco SRL filed Critical Alesco SRL
Publication of WO2021090214A2 publication Critical patent/WO2021090214A2/fr
Publication of WO2021090214A3 publication Critical patent/WO2021090214A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation de berbérine sous forme solide, appelée « berbérine sucrosomial® », comprenant ou, en variante, constitué de berbérine, d'une lécithine et d'un premier agent choisi parmi un sucrester, une cyclodextrine, un acide gras et un dérivé de chitosane, de préférence un sucrester. En outre, la présente invention concerne des compositions comprenant ladite berbérine sucrosomial® et, de manière facultative, du riz rouge et son utilisation dans le traitement d'un état de dyslipidémie ou d'une déficience du métabolisme des lipides, en particulier l'hypercholestérolémie, et/ou la déficience du métabolisme du glucose.
PCT/IB2020/060383 2019-11-04 2020-11-04 Berbérine bertrypanosomial®, ses compositions et leur utilisation Ceased WO2021090214A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IT102019000020316A IT201900020316A1 (it) 2019-11-04 2019-11-04 Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico
IT102019000020300 2019-11-04
IT102019000020290A IT201900020290A1 (it) 2019-11-04 2019-11-04 Berberina sucrosomiale®, sue composizioni e loro uso
IT102019000020300A IT201900020300A1 (it) 2019-11-04 2019-11-04 Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie
IT102019000020290 2019-11-04
IT102019000020316 2019-11-04

Publications (2)

Publication Number Publication Date
WO2021090214A2 WO2021090214A2 (fr) 2021-05-14
WO2021090214A3 true WO2021090214A3 (fr) 2021-06-10

Family

ID=73695080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/060383 Ceased WO2021090214A2 (fr) 2019-11-04 2020-11-04 Berbérine bertrypanosomial®, ses compositions et leur utilisation

Country Status (1)

Country Link
WO (1) WO2021090214A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200003224A1 (it) * 2022-03-01 2023-09-01 Neilos S R L “Composizione nutraceutica o farmaceutica comprendente un estratto di riso rosso fermentato”
IT202200007388A1 (it) * 2022-04-13 2023-10-13 Anvest Group S R L Composizione per il trattamento della ipercolesterolemia
CN115212182A (zh) * 2022-07-01 2022-10-21 广州长生康生物科技有限公司 一种大豆磷脂软胶囊及其制备方法和应用
IT202200025929A1 (it) * 2022-12-19 2024-06-19 Akhynex S R L Composizioni comprendenti frazioni di frutto di bergamotto

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009814A1 (fr) * 1994-09-29 1996-04-04 Andaris Limited Microparticules sechees par pulverisation utilisees comme excipient therapeutique
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
CN1269478C (zh) * 2004-06-14 2006-08-16 湖北丽益医药科技有限公司 盐酸小檗碱微囊及其制备方法
CN1273133C (zh) * 2004-11-12 2006-09-06 北京昭衍博纳新药研究有限公司 掩味盐酸小檗碱颗粒及其制剂
WO2007113748A1 (fr) * 2006-03-30 2007-10-11 Rottapharm S.P.A. Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine
EP2149377A1 (fr) * 2008-07-29 2010-02-03 Velleja Research SRL Compositions contenant de la berbérine et/ou ses analogues ou des extraits la contenant, pour la prévention et le traitement des altérations de l'équilibre des lipides et des hydrates de carbone
CN102525952A (zh) * 2011-11-29 2012-07-04 昆明邦宇制药有限公司 一种黄连素微丸的生产方法
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
CN104940167A (zh) * 2015-06-05 2015-09-30 厦门大学 一种负载黄连素磷脂复合纳米微粒的制备方法
WO2017027971A1 (fr) * 2015-08-17 2017-02-23 Delivra Inc. Formulations transdermiques pour l'administration de composés de berbérine et leur utilisation dans le traitement de maladies et de pathologies sensibles à la berbérine
CN106511260A (zh) * 2016-12-05 2017-03-22 黑龙江童医生儿童生物制药有限公司 一种盐酸小檗碱口服微丸干凝胶及其制备方法和应用
CN108685870A (zh) * 2017-04-06 2018-10-23 中国医学科学院药物研究所 小檗碱及其可形成盐的肠溶微丸、其制备及应用
WO2019038430A1 (fr) * 2017-08-25 2019-02-28 Eleonor Sprl Composition comprenant au moins un alcaloïde de type protoberbérine et son procédé de production
WO2019150225A1 (fr) * 2018-02-02 2019-08-08 Indena S.P.A. Compositions comprenant de la berbérine
CN106038488B (zh) * 2016-07-19 2019-08-23 重庆医科大学 一种明显提高难溶性药物生物利用度的水包油型纳米乳及其制备方法

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
WO1996009814A1 (fr) * 1994-09-29 1996-04-04 Andaris Limited Microparticules sechees par pulverisation utilisees comme excipient therapeutique
CN1269478C (zh) * 2004-06-14 2006-08-16 湖北丽益医药科技有限公司 盐酸小檗碱微囊及其制备方法
CN1273133C (zh) * 2004-11-12 2006-09-06 北京昭衍博纳新药研究有限公司 掩味盐酸小檗碱颗粒及其制剂
WO2007113748A1 (fr) * 2006-03-30 2007-10-11 Rottapharm S.P.A. Formulation orale présentant des effets cardiovasculaires bénéfiques comprenant de la berbérine
EP2149377A1 (fr) * 2008-07-29 2010-02-03 Velleja Research SRL Compositions contenant de la berbérine et/ou ses analogues ou des extraits la contenant, pour la prévention et le traitement des altérations de l'équilibre des lipides et des hydrates de carbone
CN102525952A (zh) * 2011-11-29 2012-07-04 昆明邦宇制药有限公司 一种黄连素微丸的生产方法
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
CN104940167A (zh) * 2015-06-05 2015-09-30 厦门大学 一种负载黄连素磷脂复合纳米微粒的制备方法
WO2017027971A1 (fr) * 2015-08-17 2017-02-23 Delivra Inc. Formulations transdermiques pour l'administration de composés de berbérine et leur utilisation dans le traitement de maladies et de pathologies sensibles à la berbérine
CN106038488B (zh) * 2016-07-19 2019-08-23 重庆医科大学 一种明显提高难溶性药物生物利用度的水包油型纳米乳及其制备方法
CN106511260A (zh) * 2016-12-05 2017-03-22 黑龙江童医生儿童生物制药有限公司 一种盐酸小檗碱口服微丸干凝胶及其制备方法和应用
CN108685870A (zh) * 2017-04-06 2018-10-23 中国医学科学院药物研究所 小檗碱及其可形成盐的肠溶微丸、其制备及应用
WO2019038430A1 (fr) * 2017-08-25 2019-02-28 Eleonor Sprl Composition comprenant au moins un alcaloïde de type protoberbérine et son procédé de production
WO2019150225A1 (fr) * 2018-02-02 2019-08-08 Indena S.P.A. Compositions comprenant de la berbérine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKHAVAN MAHDAVI SAHAR ET AL: "Microencapsulation optimization of natural anthocyanins with maltodextrin, gum Arabic and gelatin", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 85, 6 January 2016 (2016-01-06), pages 379 - 385, XP029412728, ISSN: 0141-8130, DOI: 10.1016/J.IJBIOMAC.2016.01.011 *
DATABASE GNPD [online] MINTEL; 16 February 2018 (2018-02-16), ANONYMOUS: "Cholesterol Control Dietary Supplement", XP055709186, retrieved from www.gnpd.com Database accession no. 5460213 *

Also Published As

Publication number Publication date
WO2021090214A2 (fr) 2021-05-14

Similar Documents

Publication Publication Date Title
WO2021090214A3 (fr) Berbérine bertrypanosomial®, ses compositions et leur utilisation
CA3242402A1 (fr) Lipides destines a etre utilises dans des formulations de nanoparticules lipidiques
WO2008061226A3 (fr) Formulations de topiramate à libération prolongée
MY173960A (en) Compositions for balancing gut microbiota and the preparation and the uses thereof
WO2011148328A3 (fr) Procédé cosmétique pour le maquillage et/ou le soin de la peau et/ou des lèvres
WO2005039597A3 (fr) Oligosaccharides immunomodulatrices
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
EP2332527A3 (fr) Flavanoides et Isoflavanoides pour la prevention et le traitement de maladies cardio-vasculaires
WO2010019239A3 (fr) Composition pharmaceutique et administrations de celle-ci
RU2009101047A (ru) Способы и композиции для улучшения когнитивной функции
WO2014170755A3 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
WO2006060618A3 (fr) Preparations topiques a base de nepafenac
MA30584B1 (fr) Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2007058874A3 (fr) Composition de conditionnement de plante systemique
WO2020146700A8 (fr) Nanoparticules lipidiques
EP4400098A3 (fr) Formes co-amorphes de beta-lactoglobuline et d'une substance medicamenteuse
WO2011141113A3 (fr) Combinaison de vitamine k et de nicotinamide
WO2019004788A3 (fr) Composition pharmaceutique comprenant de la broussochalcone a à titre de principe actif pour la prévention ou le traitement d'une maladie inflammatoire de l'intestin
JP2017001966A5 (fr)
WO2011159491A8 (fr) Formulations de lévétiracétam à libération contrôlée
WO2012019010A3 (fr) Formulations antiacides et procédés associés
WO2006110810A3 (fr) Polymorphes de di-n-methyle-d-glucamined'acide 3-o-(3',3'-dimethylsuccinyle) betulinique
WO2009007622A3 (fr) Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation
EP2586432A3 (fr) Co-cristaux de Tramadol et NSAID tels que des Coxibs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20817482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20817482

Country of ref document: EP

Kind code of ref document: A2